Trial Profile
Maintenance treatment with Lanreotide in Patients with small cell lung cancer (LD/ED) expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jul 2020
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Jul 2020 Status changed from recruiting to completed.
- 09 Sep 2015 Interim results (n=53) presented at the 16th World Conference on Lung Cancer.
- 28 Nov 2012 New trial record